Khiron Sets A Milestone As First Colombian Medical Cannabis Company To Export To Europe
April 5th, 2021
Khiron Life Sciences (TSX.V: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) (“Khiron” or the “Company”) is a vertically integrated cannabis leader with core operations in Latin America and Europe. As cannabis legalization expands globally, Prohibition Partners’ stats predict by 2024 the European market will be worth nearly $2.5 billion, and many want in. Some companies have already taken steps to get their foot in the door, Khiron Life Sciences among them.
Leading the Way Overseas
In a recent press release, Khiron announced its achievement in transporting live clone cannabis strains from its Colombia-based cultivation site to Europe. The company seeks to grow its existing European offering, currently in the United Kingdom (U.K.) and Germany, by introducing dried flower and cannabis-based medicinal products. These products’ efficacy and safety continue to be validated in Colombia and Peru, where over 13,000 prescriptions have been written to date.
In collaboration with Nimbus Health, a leading medical cannabis distributor in Germany, Khiron is now positioned for imminent first sales in Germany. Khiron products are currently in inventory in the Nimbus warehouse, ready to be prescribed to patients and distributed through a vast network of 300 pharmacies across Germany.
Khiron is confident that its model has been proven in cultivation, strain, process, delivery systems and IP developed through clinics. Because of this, the company expects to accelerate the production and delivery of EU-GMP-certified medical cannabis products through its European team of contract manufacturing and distribution partners.
One way the company is adapting to the EU market will be via its delivery systems — dried flower as opposed to extract or medicinal preparations that are used within Colombian and other Latin American markets.
How Plant Clones Work
“A clone is a cannabis plant that is a genetic copy of a mother plant. These clones were cut from our THC and CBD-bearing mother plants in Colombia, which are used to make medicines for thousands of our patients in LatAm, over 13,000 paid prescriptions to date and growing quickly,” commented Tejinder Virk, Khiron’s managing director and president of its European team.
He added, “Europe has a population of nearly 748 million people and there is enormous patient need for cannabis-based medicines. However, doctors in Europe need solid clinical evidence to confidently prescribe medical cannabis for ailments such as pain, sleep, anxiety, etc. By replicating our Colombian magistrals as EU GMP-certified medicines, we aim at providing European doctors with practical, clinical evidence from Colombia. This will also help ensure European patients get safe and efficacious treatment.”
Khiron believes that its medical cannabis products have shown strong evidence as alternative treatments for ailments such as chronic pain, anxiety, insomnia, depression, epilepsy, migraines and Parkinson’s disease. As the company’s vertically-integrated seed-to-patient business model experiences tremendous success in Colombia, it predicts equal results overseas.
About the Company
Khiron Life Sciences is a vertically-integrated medical and CPG cannabis company with core operations in Latin America and operational activity in Europe and North America. Khiron is the first company licensed in Colombia for cultivation, production, domestic distribution and sales, as well as international export of both low and high THC medical cannabis products. Its Wellbeing unit launched the first CBD skincare brand in Colombia with Kuida™, now marketed in multiple jurisdictions in Latin America, the U.S. and the U.K.
Khiron’s products are manufactured in GMP GEP-compliant facilities in Colombia, where they are standardized and stabilized according to the U.S. Pharmacopeia analytics standard (USP42). The company’s current cultivation area is 80,000 sq. ft. with up to 20 hectares available for expansion. This could be considered small compared to other global companies, but Khiron believes it’s sufficient for its demand.
The company has filled medical cannabis prescriptions in Colombia, Peru and the U.K., and is positioned to begin sales of medical cannabis in Germany and Brazil in early 2021.
Khiron is led by Co-Founder and CEO Alvaro Torres, together with an experienced and diverse executive team and board of directors. Its mission is to improve the quality of life of patients and consumers through the applied use of cannabis and technology. The Company’s vision is to reach 1 million patients and consumers by 2024.
To read Khiron’s full press release go HERE.
To access more info on Khiron Life Sciences visit investors.khiron.ca.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.